Drug Profile
Prostate cancer DNA vaccine - Genvax/University of Southampton
Alternative Names: Electroporation-delivered DNA vaccine against prostate cancer - Inovio/University of Southampton; GVX-3322Latest Information Update: 11 May 2010
Price :
$50
*
At a glance
- Originator University of Southampton
- Developer Genvax; University of Southampton
- Class Cancer vaccines; DNA vaccines; Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 05 Aug 2009 Immunogenicity data from a phase I/II trial in Prostate cancer released by Inovio
- 18 Dec 2008 Interim immunogenicity & adverse events data from a phase I/II trial in Prostate cancer presented at the DNA Vaccines 2008 Conference (DNA Vaccines-2008)
- 31 Oct 2005 Phase-I/II clinical trials in Prostate cancer in United Kingdom (IM)